Anistreplase [anistreplasa]
- Terms
-
anistrepláza
APSAC
eminasa
emináza
iminasa
imináza
-
Anisoylated Plasminogen-Streptokinase Activator Complex
APSAC
BRL-26921
Eminase
Iminase
An acylated inactive complex of streptokinase and human lysine-plasminogen. After injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis. Its half-life is about 90 minutes compared to 5 minutes for TPA; (TISSUE PLASMINOGEN ACTIVATOR); 16 minutes for UROKINASE-TYPE PLASMINOGEN ACTIVATOR and 23 minutes for STREPTOKINASE. If treatment is initiated within 3 hours of onset of symptoms for acute myocardial infarction, the drug preserves myocardial tissue and left ventricular function and increases coronary artery patency. Bleeding complications are similar to other thrombolytic agents.
- DUI
- D016255 MeSH Browser
- CUI
- M0024829
- CAS
- Anistreplase
- Previous indexing
- Fibrinolytic Agents (1966-1990); Plasminogen (1966-1990); Streptokinase (1966-1990)
- History note
- 91
- Public note
- 91
Allowable subheadings
- AD
- administration & dosage 1
- AE
- adverse effects
- AN
- analysis
- AI
- antagonists & inhibitors
- BI
- biosynthesis
- BL
- blood
- CF
- cerebrospinal fluid
- CS
- chemical synthesis
- CH
- chemistry
- CL
- classification
- DF
- deficiency
- DE
- drug effects
- EC
- economics
- GE
- genetics
- HI
- history
- IM
- immunology
- IP
- isolation & purification
- ME
- metabolism
- PK
- pharmacokinetics
- PD
- pharmacology 1
- PH
- physiology
- PO
- poisoning
- RE
- radiation effects
- ST
- standards
- SD
- supply & distribution
- TU
- therapeutic use 1
- TO
- toxicity
- UL
- ultrastructure
- UR
- urine